A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib).
Members of the Oncologic Drugs Advisory Committee expressed concerns that the data wasn't strong
